Targeted Therapy Improves Long-Term Outcomes for Patients with Rare Mutations Driving Lung Cancer
Mass General Brigham Cancer Institute study found that patients with advanced RET fusion-positive lung cancer showed robust and durable responses.
Press Release5 Minute ReadJun | 27 | 2022
BOSTON –A healthcare system model that offered tobacco cessation treatment to smokers being discharged from a hospital produced a higher rate of tobacco abstinence during the three- month program than referral to a state-based telephone quitline, but the advantage disappeared at six months when both treatments produced comparable quit rates, researchers from Massachusetts General Hospital (MGH) have found. In a study in JAMA Internal Medicine, the team suggested that extension beyond three months of the health system approach, which includes cessation medication and telephone-based behavioral support, could potentially keep individuals tobacco-free.
“Hospital admission is a great opportunity for smokers to begin tobacco cessation treatment,” says lead author Nancy Rigotti, MD, director of the MGH Tobacco Research and Treatment Center. “That treatment is only effective, however, if it continues after discharge. How to best meet that ongoing need is the question our study was designed to address.”
Cigarette smoking is responsible for around 480,000 deaths annually, the leading cause of preventable deaths in the United States. In 2020, an estimated 13 percent of adults were regular smokers, and more than 3.2 million of them were admitted to a hospital. Researchers from MGH, Vanderbilt University Medical Center, and University of Pittsburgh Medical Center conducted a study of 1,409 adults who smoked and received brief in-hospital tobacco treatment at one of these medical centers to determine the most effective post-discharge model for cessation.
Participants were randomized to one of two models, each offering tobacco cessation medication and counseling by telephone for up to three months. One model used the national system of state-based telephone quitlines, which provides cessation counseling and free samples of nicotine patches, gum, or lozenges. The medical center model provided people who smoked with nicotine medications at hospital discharge and continued counseling with a series of automated and live phone calls.
The study found that three months after discharge, more participants in the healthcare system model were tobacco-free for at least seven days (which was biochemically verified), compared to the quitline model. But at six months -- three months after healthcare system intervention ended -- the difference in smoking abstinence rates between the two models had narrowed and was not statistically significant.
“Our findings prompt the question of whether continuing smoking cessation past three months -- the standard duration of treatment -- would sustain the superior results of the healthcare system model,” says senior author Hilary Tindle, MD, MPH, founding director of the Vanderbilt Center for Tobacco Addiction and Lifestyle. “It’s possible that more counseling or medication, or both, could generate more engagement with the program and thus better results over time.”
That thought was echoed by co-author Esa Davis, MD, MPH, director of the University of Pittsburgh Medical Center Tobacco Treatment Service. “We found that keeping smoking cessation within the healthcare system where it could be managed like other chronic medical conditions could be an effective form of treatment,” she remarked. “This approach presents a challenge for healthcare systems, however, which future research needs to address.”
Rigotti is professor of Medicine, Harvard Medical School (HMS) and associate chief for academic advancement, Division of General Internal Medicine, MGH. Tindle is associate professor of Medicine, HMS. Davis is associate professor of Medicine, University of Pittsburgh Medical Center.
The study was funded by the National Heart, Lung, and Blood Institute.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in the U.S. News & World Report list of "America’s Best Hospitals." MGH is a founding member of the Mass General Brigham healthcare system.
Mass General Brigham Cancer Institute study found that patients with advanced RET fusion-positive lung cancer showed robust and durable responses.
Mass General Brigham researchers used artificial intelligence to analyze routine medical scans, uncovering how the thymus impacts aging, cardiovascular risk, cancer incidence, and response to immunotherapy.
Mass General Brigham has received a $50 million gift that will shape the future of cancer care and discovery by empowering the next generation of gene and cell therapy research.
The Sean M. Healey & AMG Center for ALS at Mass General Brigham has contracted with Keros Therapeutics, Inc. (Keros) to design a new Healey ALS MyMatch trial evaluating rinvatercept (KER-065).
The Sean M. Healey & AMG Center for ALS at Mass General Brigham is pleased to announce that the first participant received study medication in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 by Neurizon Therapeutics.
Investigators from Mass General Brigham analyzed data from nearly 4,300 stable outpatients with chest pain and no known prior CAD and found that, although women had smaller plaque volumes and fewer plaques with high-risk characteristics, they experienced similar rates of MACE compared with men.